Algernon Pharmaceuticals Announces Name Change to Algernon Health
Algernon Pharmaceuticals (OTCQB: AGNPF) has announced its rebranding to Algernon Health, marking a strategic shift towards the Alzheimer's Disease (AD) diagnostic market. The company plans to establish specialized neuroimaging clinics across North America, featuring FDA-cleared brain-specific PET scanning systems that offer lower radiation exposure compared to standard PET/CT machines.
The company's clinics will provide essential amyloid plaque detection services required for FDA-approved AD treatments like Kisunla and Leqembi. These diagnostic services are covered by Medicare, Medicaid, and private insurance in the U.S. The clinics will also offer PET scans for other neurological conditions, including dementia, epilepsy, neuro-oncology, and movement disorders.
Algernon maintains its subsidiary Algernon NeuroScience, focused on DMT research for stroke and brain injury, and holds a 20% stake in Seyltx, which is developing a chronic cough drug.
Algernon Pharmaceuticals (OTCQB: AGNPF) ha annunciato il cambio di nome in Algernon Health, segnando una svolta strategica verso il mercato della diagnostica della malattia di Alzheimer (AD). L'azienda intende aprire cliniche specializzate in neuroimaging in Nord America, dotate di sistemi PET cerebrali approvati dalla FDA che garantiscono un'esposizione alle radiazioni inferiore rispetto ai tradizionali apparecchi PET/CT.
Le cliniche offriranno il servizio di rilevamento delle placche amiloidi necessario per i trattamenti AD approvati dalla FDA come Kisunla e Leqembi. Queste prestazioni diagnostiche sono coperte da Medicare, Medicaid e assicurazioni private negli Stati Uniti. Saranno inoltre disponibili PET per altre patologie neurologiche, tra cui demenza, epilessia, neuro-oncologia e disturbi del movimento.
Algernon mantiene la controllata Algernon NeuroScience, impegnata nella ricerca di DMT per ictus e lesioni cerebrali, e detiene una partecipazione del 20% in Seyltx, che sta sviluppando un farmaco per la tosse cronica.
Algernon Pharmaceuticals (OTCQB: AGNPF) ha anunciado su cambio de nombre a Algernon Health, marcando un giro estratégico hacia el mercado de diagnóstico de la enfermedad de Alzheimer (EA). La compañía planea abrir clínicas especializadas en neuroimagen en Norteamérica, equipadas con sistemas PET cerebrales aprobados por la FDA que implican una menor exposición a la radiación en comparación con las máquinas PET/CT convencionales.
Las clínicas ofrecerán la detección de placas amiloides necesaria para tratamientos de EA aprobados por la FDA como Kisunla y Leqembi. Estos servicios diagnósticos están cubiertos por Medicare, Medicaid y seguros privados en EE. UU. También se realizarán PET para otras afecciones neurológicas, incluidas demencia, epilepsia, neuro-oncología y trastornos del movimiento.
Algernon mantiene su subsidiaria Algernon NeuroScience, centrada en la investigación de DMT para ictus y lesiones cerebrales, y posee una participación del 20% en Seyltx, que desarrolla un fármaco para la tos crónica.
Algernon Pharmaceuticals (OTCQB: AGNPF)가 사명을 Algernon Health로 변경한다고 발표했습니다. 이는 알츠하이머병(AD) 진단 시장으로의 전략적 전환을 의미합니다. 회사는 북미 전역에 특화된 신경영상 클리닉을 설립할 계획이며, 기존 PET/CT 장비보다 방사선 노출이 낮은 FDA 승인 뇌 전용 PET 스캐닝 시스템을 도입할 예정입니다.
클리닉은 Kisunla와 Leqembi와 같은 FDA 승인 AD 치료제에 필요한 아밀로이드 플라크 검출 서비스를 제공할 것입니다. 이 진단 서비스는 미국에서 Medicare, Medicaid 및 민간 보험으로 보장됩니다. 또한 치매, 간질, 신경종양, 운동장애 등 기타 신경계 질환에 대한 PET 검사도 제공됩니다.
Algernon은 뇌졸중 및 뇌 손상 대상 DMT 연구를 진행하는 자회사 Algernon NeuroScience를 유지하고 있으며, 만성 기침 약물을 개발 중인 Seyltx의 20% 지분을 보유하고 있습니다.
Algernon Pharmaceuticals (OTCQB: AGNPF) a annoncé son changement de nom en Algernon Health, marquant une réorientation stratégique vers le marché du diagnostic de la maladie d'Alzheimer (MA). La société prévoit d'ouvrir des cliniques spécialisées en neuroimagerie en Amérique du Nord, équipées de systèmes de PET cérébral agréés par la FDA, offrant une exposition aux radiations inférieure à celle des appareils PET/CT standard.
Les cliniques proposeront la détection des plaques amyloïdes nécessaire aux traitements MA approuvés par la FDA tels que Kisunla et Leqembi. Ces services diagnostiques sont couverts par Medicare, Medicaid et les assurances privées aux États-Unis. Des PET pour d'autres affections neurologiques seront également proposés, y compris la démence, l'épilepsie, la neuro-oncologie et les troubles du mouvement.
Algernon conserve sa filiale Algernon NeuroScience, axée sur la recherche DMT pour les AVC et les lésions cérébrales, et détient une participation de 20% dans Seyltx, qui développe un médicament contre la toux chronique.
Algernon Pharmaceuticals (OTCQB: AGNPF) hat angekündigt, sich in Algernon Health umzubenennen und damit eine strategische Ausrichtung auf den Diagnosemarkt für Alzheimer-Krankheit (AD) vorzunehmen. Das Unternehmen plant die Errichtung spezialisierter Neuroimaging-Kliniken in Nordamerika, ausgestattet mit von der FDA zugelassenen, gehirnspezifischen PET-Scannern, die eine geringere Strahlenbelastung als herkömmliche PET/CT-Geräte bieten.
Die Kliniken werden die für FDA-zugelassene AD-Therapien wie Kisunla und Leqembi erforderliche Amyloid-Plaque-Erkennung anbieten. Diese diagnostischen Leistungen werden in den USA von Medicare, Medicaid und privaten Versicherungen übernommen. Zudem werden PET-Untersuchungen für weitere neurologische Erkrankungen wie Demenz, Epilepsie, Neuroonkologie und Bewegungsstörungen angeboten.
Algernon behält seine Tochtergesellschaft Algernon NeuroScience bei, die sich auf DMT-Forschung für Schlaganfall und Hirnverletzungen konzentriert, und hält eine 20%-Beteiligung an Seyltx, das ein Medikament gegen chronischen Husten entwickelt.
- Entry into the growing AD diagnostic market with FDA-cleared technology
- Services covered by Medicare, Medicaid, and private insurance ensuring revenue stream
- Strategic positioning in an underserved market with insufficient PET scanners for brain scanning
- Additional revenue potential from clinical trial imaging services for 162 AD drugs under development
- Diversified service offering including PET scans for other neurological conditions
- Significant shift from pharmaceutical development to diagnostic services indicates change in business model
- Will require substantial capital investment for clinic establishment and equipment
- Faces potential competition from established healthcare providers
VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company announces that it is changing its name to Algernon Health.
The planned name change reflects the Company’s recent announcement that it will be focusing on the Alzheimer’s Disease (AD) diagnostic market with plans to establish specialized neuroimaging clinics across North America as its lead program. The clinics will feature the latest technology of U.S. FDA-cleared, optimized brain-specific Positron Emission Tomography (PET) scanning systems to detect amyloid plaques in patients, providing significantly lower radiation compared to standard PET/CT machines currently in operation globally. The PET scans are covered by Medicare, Medicaid, and private insurance in the U.S.
Amyloid plaques are aggregates of mis-folded proteins that form in the spaces between nerve cells and are known to play a central role in AD and are associated with neural degeneration. The amyloid plaques typically first develop in the areas of the brain concerned with memory and other cognitive functions. A positive amyloid confirmation through a PET scan or a spinal tap must be first established before a patient can be treated with either Kisunla or Leqembi, the two U.S. FDA-approved, AD monoclonal antibody treatment therapies that remove amyloid plaque from the brain. These new treatments were developed by Eli Lilly, and Eisai and Biogen, respectively, and are also covered by U.S. Medicare, Medicaid, and private insurance providers.
After the first AD drug treatment was approved, in a post-earnings call, GE HealthCare CEO Peter Arduini called it a “profound growth opportunity” for all providers offering PET scans and molecular imaging.
The introduction of dedicated neuroimaging clinics provides the Company with a clear pathway to revenue utilizing a technology already U.S. FDA-cleared and covered by U.S. Medicare and Medicaid and private insurance. The Algernon clinics will also offer additional brain PET scans for other forms of dementia, epilepsy, neuro-oncology, and movement disorders, to further expand the provision of healthcare to patients in need and expand clinic revenues.
This strategic entry by Algernon into dedicated neuroimaging clinics is significantly based on the fact that the vast majority of PET/CT scanners in the U.S. are prioritized as cancer diagnostic and theranostic tools, and are also dedicated to cardiac imaging. Consequently, there is an insufficient supply of scanners to serve the rapidly expanding AD diagnostics market.
The shortage of PET scanners for brain specific scanning also has an impact beyond immediate patient care. With 162 AD drugs under development, there is also a significant opportunity to provide brain specific PET scan imaging services to drug development companies and contract research organizations engaged in clinical trials, as another source of revenue for Algernon.
Algernon will update the market shortly on its upcoming expansion and growth plans including the location of it first U.S. flagship neuroimaging clinic.
Algernon continues to be the parent company of a private subsidiary called Algernon NeuroScience that has been advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury. The Company also owns a
Algernon is currently reviewing its repurposed chronic kidney disease drug program which features the drug repirinast as its lead molecule.
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com
About Algernon Health
Algernon Health is a Canadian healthcare company focused on the provision of brain specific PET scanning services through a planned network of new clinics in North America for the detection of Alzheimer’s disease, as well as other forms of dementia, epilepsy, neuro-oncology, and movement disorders. Algernon is also the parent company of a private subsidiary called Algernon NeuroScience that has been advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury. The Company also owns a
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
FAQ
Why is Algernon Pharmaceuticals (AGNPF) changing its name to Algernon Health?
What services will Algernon Health's neuroimaging clinics offer?
How will Algernon Health generate revenue from its neuroimaging clinics?
What other business segments does Algernon Health maintain?
What advantage does Algernon Health have in the AD diagnostic market?
